[1] Hutt, V.; Waitzinger, J.; Macchi, F. Clin. Drug Invest. 2001, 21, 361-369. [2] Rao, R.N.; Meena, S.; Rao, A.R. J. Pharm. Biomed. Anal. 2005, 39, 349-363. [3] Guptau, S.K.; Bhardwaj, R.K.; Tyagi, P.; Sengupta, S.; Velpandian, T. Pharmacol. Res. 1999, 39, 137-141. [4] Jaworowicz Jr., D.J.; Filipowski, M.T.; Boje, K.M.K. J. Chromatogr. B. 1999, 723, 293-299. [5] Starek, M.; Krzek, J. Talanta. 2009, 77, 925-942. [6] Bernareggi, A. Clin. Pharmacokinet. 1998, 35, 247-274. [7] Huo, Q.; Li, J.C.; Ma, T.; Zhu, X.G.; Jiang, Z.W. J. Huaihai Med. 2009, 27, 22-24. [8] Tian, J.; Ran, L.L.; Zhou, Y.B.; Ding, J.S. Chin. Pharm. J. 2008, 43, 1100-1102. [9] Ren, J.M.; Kang, Z.K.; Wang, C.P.; Xie, X.Y.; Yin, L.X. China Pharmacy. 2008, 119, 104-105. [10] Ferrario, P.; Bianchi, M. J. Chromatogr. B. 2003, 785, 227-236. [11] Liu, W.; Li, X.Y.; Cheng, W.M. China Pharmacy. 2010, 21, 143-144. [12] Barrientos-Astigarraga, R.E.; Vannuchi, Y.B.; Sucupira, M.; Moreno, R.A.; Muscara, M.N.; Nucci, G.D. J. Mass Spectrom. 2001, 36, 1281-1286. [13] Hoyo-Vadillo1, C.; Escobar, Y.; Escobar-Islas, E.; Venturelli, C.R. Proc. West. Pharmacol. Soc. 2003, 46, 168-196. [14] Guidance for bioavailability and bioequivalence studies for Chemical pharmaceutical preparations (updated 2005). http://www.sda.gov.cn/gsz05106/08.pdf. [15] Guidance for industry, Bioanalytical method validation (updated 2001). http://www.fda.gov/cder/guidance/index.htm |